HOME › DRUGS › INOTUZUMAB OZOGAMICIN
ACTIVE SUBSTANCE / INN

INOTUZUMAB OZOGAMICIN

Brand name(s): Besponsa, BESPONSA
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BLA761040
ACTIVE SUBSTANCE
Inotuzumab Ozogamicin
REGULATORS
FDA · EMA
SPONSORS / MAH
WYETH PHARMS INC, Pfizer Europe MA EEIG
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
BESPONSABLA761040WYETH PHARMS INCPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
BesponsaPfizer Europe MA EEIGAuthorised28/06/2017Precursor Cell Lymphoblastic Leukemia-Lymphoma

FULL INTELLIGENCE ON INOTUZUMAB OZOGAMICIN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →